Marginal Zone B-cell Lymphoma Clinical Trial
Official title:
A Phase II Study of Bendamustine Plus Rituximab (BR) in Patients With Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)
This study will be conducted to evaluate the efficacy of Bendamustine Plus Rituximab (BR) in patients with relapsed or progressive Marginal Zone B-cell Lymphoma (MZBCL).
Multi-center trial, Phase II, non-randomized, open-label, single-arm study with combined therapy of bendamustine and rituximab in patients with MZBCL who has relapsed or progressive to prior chemotherapy or chemo-radiotherapy. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT02722668 -
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
|
Phase 2 | |
| Recruiting |
NCT03314974 -
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
|
Phase 2 | |
| Recruiting |
NCT02086591 -
A Phase II Study of Doxycycline in Relapsed NHL
|
Phase 2 | |
| Completed |
NCT01164267 -
Multicenter Phase II Study to Evaluate the Clinical Activity and the Safety Profile of Everolimus in Marginal Zone B-cell Lymphomas (MZL)
|
Phase 2 | |
| Completed |
NCT02853370 -
Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma
|
Phase 2 | |
| Completed |
NCT00783367 -
Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas
|
Phase 2 | |
| Withdrawn |
NCT01163201 -
T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies
|
Phase 1/Phase 2 | |
| Terminated |
NCT02991898 -
Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies
|
Phase 2 | |
| Recruiting |
NCT01962636 -
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
|
N/A |